Japan's Astellas Pharma maintains full-year profit forecast amid overseas M&A

Japan’s Astellas Pharma Inc reiterated its full–year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug drug countered overseas acquisition costs.